Cel-Sci (NYSEAMERICAN:CVM) Trading 10% Higher – Here’s What Happened

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s stock price traded up 10% during trading on Friday . The stock traded as high as $1.5599 and last traded at $1.43. 1,114,174 shares traded hands during mid-day trading, an increase of 59% from the average session volume of 700,046 shares. The stock had previously closed at $1.30.

Cel-Sci Stock Up 10.0%

The company has a market capitalization of $12.14 million, a PE ratio of -0.15 and a beta of 0.70. The company has a quick ratio of 1.35, a current ratio of 1.39 and a debt-to-equity ratio of 0.45. The firm has a 50-day moving average of $3.29 and a two-hundred day moving average of $4.92.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CVM. Bank of America Corp DE grew its position in Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after acquiring an additional 39,190 shares during the period. Vanguard Group Inc. grew its position in Cel-Sci by 59.7% in the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after acquiring an additional 109,352 shares during the period. MAI Capital Management grew its position in Cel-Sci by 18.4% in the third quarter. MAI Capital Management now owns 76,861 shares of the company’s stock worth $707,000 after acquiring an additional 11,928 shares during the period. US Bancorp DE purchased a new position in Cel-Sci in the third quarter worth approximately $80,000. Finally, HighTower Advisors LLC purchased a new position in Cel-Sci in the fourth quarter worth approximately $53,000. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.